From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Siri: Show me an interviewer who makes Justin the Clown seem like Jeremy Paxman – ref Scotgold & Katie Pilbeam

By Tom Winnifrith, The Sheriff of AIM | Tuesday 27 April 2021


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Companies like Scotgold (SGZ) pay Proactive to record soft interviews and so anyone engaged in this process is part of a bent and corrupt bastard child of journalism. This is PR dressed up as reporting. I have seen some rotten Proactive blow-offs in my time but today’s effort from Katie Pilbeam on Scotgold is the worst ever. She makes Justin the Clown look like Jeremy Paxman in his prime. Watch and cringe. It is so bad it is actually truly enjoyable, you really will laugh out loud.

You must be a registered member to read this story
ShareProphets is reader-supported journalism

Join us for free and gain access to three articles per month

Or become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 13:11:50